| Components of Accrued Expenses and Other Long-Term Liabilities |
Accrued expenses and other long-term liabilities, excluding National, consisted of the following: | | | September 30, | | | December 31, | | | ($ in thousands) | | 2017 | | | 2016 | | | Accrued expenses: | | | | | | | | | | Professional fees | | $ | 1,297 | | | $ | 1,253 | | | Salaries, bonuses and related benefits | | | 4,178 | | | | 2,846 | | | Accrued Severance | | | - | | | | 53 | | | Accrued Legal Settlement (1) | | | 2,212 | | | | - | | | Ovamed manufacturing rights - short term component | | | - | | | | 900 | | | Research and development | | | 3,311 | | | | 394 | | | Dr. Falk Pharma milestone | | | 2,950 | | | | 2,634 | | | Other | | | 2,703 | | | | 2,002 | | | Total accrued expenses | | $ | 16,651 | | | $ | 10,082 | | | | | | | | | | | | | Other long-term liabilities: | | | | | | | | | | Deferred rent and long-term lease abandonment charge | | | 4,736 | | | | 5,014 | | | Total other long-term liabilities | | $ | 4,736 | | | $ | 5,014 | |
| (1) | In connection with a legal settlement (see Note 16), the Company is required to deliver 200,000 Mustang common shares, held by the Company, to the Plaintiff. At September 30, 2017, the Company recorded, this settlement as an accrued, since in accordance with ASC 450 Contingencies, the transfer of the consideration was probable. As such the Company recorded an accrued expense of $2.0 million representing the value of the shares transferred. |
|
| Components of Accrued Expenses and Other Long-Term Liabilities |
National's accounts payable and other accrued expenses as of June 30, 2017, consisted of the following: | | | June 30, | | | | | 2017 | | | Legal | | $ | 836 | | | Audit | | | 148 | | | Telecommunications | | | 196 | | | Data Services | | | 450 | | | Regulatory | | | 661 | | | Settlements | | | 2,633 | | | Deferred rent | | | 177 | | | Contingent consideration payable | | | 636 | | | Income taxes payable | | | 927 | | | Other | | | 1,844 | | | Total | | $ | 8,508 | |
|